Moschovakis Capital

UnitedHealth Group Incorporated

UNH

EQUITY RESEARCH REPORT

September 16, 2026

CONFIDENTIAL — FOR INFORMATIONAL PURPOSES ONLY | NOT INVESTMENT ADVICE

UNH — UnitedHealth Group Incorporated

Report Date: 2026-09-16

Analyst: Moschovakis Capital Research

EXECUTIVE SUMMARY

Metric	Value
Recommendation	BUY
Current Price	$375.93 USD / €325.71 EUR
Fair Value (Base Case)	$500.00 USD / €433.20 EUR
Margin of Safety	33.0%
Target Entry (if HOLD)	Not applicable

Return Profile	Value
Dividend Yield	2.35%
Expected Dividend Growth	5.0% (forward assumption; not independently verified)
Expected Price Appreciation	5.9% annual (base case)
Total Expected Return (Base)	8.3% CAGR
Bear Case Total Return	0.5% CAGR
Bull Case Total Return	12.8% CAGR
Probability-Weighted Return	7.5% CAGR

Risk Assessment	Value
Wealth Preservation Score	66 / 100
Downside Protection Score	60 / 100
Quality Score	73 / 100
Risk Level	MODERATE
Probability of >50% Loss	<5% (qualitative estimate)
Recession Profile	RESILIENT (recession) / SENSITIVE (regulatory)

One-Line Thesis:

UNH owns a dominant U.S. insurance franchise and an Optum services platform; the 2024-2025 earnings collapse is a regulatory and right-sizing trough, and at $375.93 the forward earnings recovery plus a 2.35% dividend clears the 7% hurdle while the bear case roughly breaks even on a total-return basis.

INVESTMENT THESIS

You are evaluating UnitedHealth Group after a public earnings collapse. The company reported $447.57 billion of revenue in fiscal 2025, up 11.8% from fiscal 2024, but net income fell to roughly $12.1 billion from $14.4 billion in 2024 and $22.4 billion in 2023. The decline came from an 89.1% consolidated medical care ratio in 2025, Medicare Advantage cost pressure, and the operational disruption that followed the Change Healthcare cyberattack. The stock de-rated from its former highs and now trades at $375.93. This is the setup, not the thesis.

UnitedHealth has two engines. UnitedHealthcare holds roughly 33.8% of U.S. accident and health insurance share and covers more than 50 million people. In Medicare Advantage, calendar 2024 data show UnitedHealth is the largest insurer in 41% of U.S. counties and the only insurer with at least 50% enrollment in 22% of counties. Optum monetizes care delivery, pharmacy benefits, analytics, and provider services. That scale is the moat. It produces provider negotiating power, data advantages, and diversified cash flow. Free cash flow stayed positive every year from fiscal 2021 through fiscal 2025 even as margins compressed.

The forward outlook is a deliberate repair. Management guided 2026 revenue above $439 billion, a 2% decline from 2025, and operating earnings above $24 billion with a net margin near 3.6%, up from 2.7%. Q1 2026 adjusted EPS was $7.23 against a $6.56 consensus, and Q2 adjusted EPS was $6.38 against a $4.85 to $4.94 consensus. The Q2 medical care ratio of 86.7% beat the 88.5% consensus by 180 basis points. Those prints do not guarantee recovery, but they confirm the repricing mechanism is working.

At $375.93, the forward P/E is about 19.1 on the 2026 consensus EPS near $19.76. The historical multiple sat around 18x during two decades of roughly 14% EPS growth. The base case assumes only 6.5% EPS growth from the 2026 base, an 18x terminal multiple, and a 2.35% dividend yield. That math returns about 8.3% annually over ten years. The hurdle is inflation plus 4%, roughly 7% today. The base case clears it. The bull case of faster Medicare Advantage rate recovery and Optum margin expansion returns about 12.8%.

The downside matters more than the upside in this mandate. If 2027 Medicare Advantage rates disappoint and the right-sizing stalls, earnings might grow only 1.6% a year and the terminal multiple might compress to 13x. That yields a $300 ten-year price target, a 20% price loss. The dividend, which UnitedHealth has paid for 24 years, adds about 2.35% annually and keeps the total return near 0.5% before inflation. You would not beat inflation in that scenario, but you would avoid permanent capital loss. The probability-weighted return across bear, base, and bull scenarios is 7.5%, still above the 4% cash alternative.

The main threats are regulatory: DOJ algorithm scrutiny, Medicare Advantage coding intensity enforcement, and CMS rate policy. These are known and visible, not hidden accounting issues. The filing data show no auditor warnings and no going concern language. Position sizing matters here. The composite wealth preservation score is 66 out of 100, which places UNH in the standard position band, not the highest-conviction tier. The score reflects moderate leverage, high regulatory exposure, and a non-fortress balance sheet. Buy it, but do not make it the entire portfolio. The October 27, 2026 earnings report is the next hard test.

---

1. BUSINESS QUALITY ASSESSMENT

UnitedHealthcare underwrites health benefits and collects premiums from employers, individuals, Medicare, and Medicaid. Optum delivers care management, pharmacy benefit management, analytics, and clinical services. The source packet does not break out segment revenue, so the analysis must treat the combined $447.57 billion revenue base. That revenue rose 11.8% in fiscal 2025 after 7.7% growth in fiscal 2024 and 14.6% in fiscal 2023. This is not a declining sector. It is a defensive, regulated industry with periodic policy shocks.

Competitive position is the strong point. UnitedHealth commanded roughly 33.8% of U.S. accident and health insurance market share as of Q3 2025, far ahead of peers. The company is the largest Medicare Advantage insurer in 41% of U.S. counties in calendar 2024 and the only insurer with at least 50% enrollment in 22% of counties. That local density matters. It gives UnitedHealthcare provider leverage and gives Optum a captive flow of claims, pharmaceutical spending, and care delivery volume. The moat is market share plus scale, not a narrow regulatory monopoly.

Optum's growth path has two sides. Pharmacy and care delivery expanded, but data analytics setbacks and rising compliance costs offset part of that growth. Change Healthcare, acquired in 2022, was hit by a serious cyberattack in 2024 that disrupted payments. The Department of Justice investigated Optum's algorithms. LHC Group, acquired in 2023, added home-based care. These acquisitions created a vertically integrated system that spans insurance, clinics, pharmacies, and analytics. That integration creates regulatory conflict because UnitedHealth acts as both payer and provider. TradingKey described the model as playing both judge and player. That is not a hidden risk; it is the main quality tradeoff.

Margins confirm the trough. Fiscal 2025 operating margin was 4.24%, down from 8.07% in fiscal 2024 and 8.71% in fiscal 2023. The trailing twelve months ended June 30, 2026 show operating margin at 7.13% and return on invested capital at 10.02%. The margin trough is visible in historical data, and early 2026 recovery is visible in the trailing figures. A 10% ROIC is value-creating but not exceptional. The moat is wide in market share, yet it can erode through policy changes. That is the key quality limitation.

Geographic exposure is overwhelmingly U.S. The company offers selected international benefits. International expansion to India, Southeast Asia, and Sub-Saharan Africa appears as optionality in one source but is not the current earnings engine. A U.S.-centric model means the framework's recession analysis matters less than the regulatory calendar. The main sector tailwind is demographic aging and the shift of seniors into Medicare Advantage. The main headwind is CMS rate adequacy and coding enforcement.

Framework gate: Stage 1 sector and theme passes. The sector is understandable, not in secular decline, defensive, and carries identifiable tailwinds and regulatory headwinds. No disqualifying sector-level condition appears.

---

2. FINANCIAL FORTRESS ANALYSIS

Solvency is ADEQUATE, not FORTRESS. Debt to equity is 0.66, inside the framework's acceptable band below 1.0 but above the preferred 0.5. Debt to EBITDA runs 3.39, and debt to FCF runs 3.96 on trailing figures. A $3 billion senior note issue across 2028 to 2055 maturities extends the maturity ladder, but the available filing data does not disclose coupons or a single maturity cliff. FilingRadar reports no auditor warnings or going concern issues. The SEC search summary states the same.

Interest coverage and current ratio were not provided in the packet. I cannot award full fortress points without those figures. The available EBITDA of $26.68 billion trailing against a plausible interest load suggests coverage remains healthy, but I will not manufacture a number. I use the midpoint scoring for interest coverage rather than

the top tier.

Free cash flow history: fiscal 2021 produced $19.89 billion, fiscal 2022 $23.40 billion, fiscal 2023 $25.68 billion, fiscal 2024 $20.71 billion, and fiscal 2025 $16.08 billion. The company generated positive FCF in every year. The decline from the 2023 peak is 37%, driven by the same margin pressure. Trailing FCF is approximately $19.7 billion, based on a 4.37% FCF margin on $450.53 billion revenue. That shows stabilization but not a return to peak. The dividend consumes about 41% of trailing FCF and about 50% of fiscal 2025 FCF, leaving a cushion.

Earnings quality is acceptable but not verifiable in full. GAAP net income is $12.06 billion for fiscal 2025 by StockAnalysis or $12.81 billion by AlphaQuery. Trailing net income is $14.12 billion. The source discrepancies are material but do not change the conclusion that profits are real and cash-backed. Operating cash flow was not provided to test against net income. The packet contains no restatement, revenue recognition issue, or auditor warning.

A 30% revenue decline for two years in a severe recession would reduce revenue from about $450 billion to about $315 billion. Even at a compressed 3% FCF margin, FCF would approximate $9.5 billion, still above the $8.1 billion annual dividend. Leverage would rise but not breach solvency. The primary stress is not a recession; it is sustained regulatory margin compression combined with a cyber or enforcement event. The balance sheet survives both, but the equity would de-rate.

Solvency Assessment: ADEQUATE. The company passes the solvency gate but does not reach fortress status because leverage is moderate, FCF has declined for two years, and key liquidity metrics are missing.

---

3. DIVIDEND ANALYSIS

UnitedHealth pays quarterly. Barchart reports the recent quarterly dividend at $2.21 per share, 24 years of payments, and an annual yield of 2.6% on a lower prior price. Yahoo Finance lists a cash dividend of $2.32 with an ex-date of September 14, 2026, which implies a $9.28 annual rate, not $8.84. The two sources conflict. I use the $2.21 quarterly figure for conservatism. That gives $8.84 annually and a 2.35% yield at the current $375.93 price. The true yield is between 2.35% and 2.47%.

Payout coverage is the main question. On trailing GAAP EPS of $15.26 to $15.54, the payout ratio is 57% to 58%. On the 2026 consensus EPS near $19.76, the payout ratio is 44.7%. On fiscal 2025 GAAP EPS of $13.23, the payout ratio is 66.9%. The dividend is covered on all three measures. FCF payout is about 41% of trailing FCF and 50% of fiscal 2025 FCF. That is sustainable even under moderate earnings stress.

Dividend growth history was not provided separately in the packet. I infer maintenance through the 2008 and 2020 recessions from the 24-year payment record, but I cannot verify the growth CAGR. The framework penalizes unverified growth. I assign dividend growth of 5.0% as a forward assumption aligned with the earnings recovery, not as historical fact.

Verdict: SUSTAINABLE, not ROCK SOLID. Coverage is strong and the record is long, but recent earnings volatility and the absence of a verified growth history prevent the higher rating. A dividend cut is not the central risk. The central risk is that the earnings recovery stalls. If that happens, the payout ratio on flattened earnings stays manageable, but total return becomes inadequate.

---

4. VALUATION ANALYSIS

The current price is $375.93. Trailing GAAP EPS ranges from $15.26 to $15.54, so trailing P/E is about 24.4. That looks expensive, but it is misleading because trailing earnings sit near the trough. The forward P/E is 19.11 on the 2026 consensus EPS near $19.76. That matches the price divided by the consensus forecast. The company's two-decade typical multiple was about 18x, so the stock is slightly above historical valuation on forward earnings but not stretched.

Metric	Current	Note
P/E trailing	24.4x	EPS $15.26 to $15.54; trough earnings
Forward P/E	19.11x	Implied 2026 EPS approximately $19.7
P/S trailing	0.78	Revenue approximately $450.5 billion
P/B	3.3 to 3.4	Book value per share $114.17
P/FCF trailing	17.8	Trailing FCF approximately $19.7 billion
EV/EBITDA	12.3	Trailing EBITDA $26.68 billion

The Stockoscope DCF, last updated July 19, 2026, assumes 4.2% growth for five years, tapering to 3.18% terminal growth, discounted at 7.45%. It reports the price at 25% below the blended estimate and 26% below the DCF estimate. A price 26% below the DCF fair value implies a fair value near $508. Using a blended fair value of $500 produces a margin of safety of ($500 - $375.93) / $375.93, or 33.0%. That is a real cushion.

Sell-side targets reinforce the range. MarketWatch's average target is $481.52, with a high of $529 from Morgan Stanley, a low of $380, and a median of $490. MarketBeat's average is $456.56. The $500 base fair value sits between the average and the high target. Upside to $500 is 33%.

Relative valuation is reasonable but not extreme. P/S of 0.78 is low for a healthcare services business, but it reflects a thin 3.1% net margin. EV/EBITDA of 12.3 is moderate. P/FCF of 17.8 is reasonable because FCF is depressed. The source packet did not provide five-year valuation averages, so I cannot assign the framework's valuation percentile precisely. I estimate the stock sits in the 25th to 50th percentile of its own valuation history because the forward P/E is near the 18x historical benchmark. That corresponds to 10 of 15 valuation points.

Conclusion: ATTRACTIVE with a 33% margin of safety against an externally computed DCF fair value, but not a statistically cheap security.

---

5. SCENARIO ANALYSIS

Scenario	2036 EPS	Terminal P/E	Price Target	Total CAGR	Weight	Contribution
Bear	$23.16	13x	$300	0.5%	25%	0.13%
Base	$37.09	18x	$668	8.3%	50%	4.15%
Bull	$51.24	20x	$1,025	12.8%	25%	3.20%
Probability-Weighted				7.5%		

The scenarios start from 2026 consensus EPS of $19.76. The base case assumes 6.5% compound growth to $37.09 by 2036, an 18x terminal multiple, and the current 2.35% dividend yield. The price target is $668. That is 5.9% annual price appreciation plus the dividend, for 8.3% total return. The base case clears the 7% hurdle but does not offer the 12%-plus return that would support a maximum position. It is an adequate return for a defensive franchise with visible regulatory risk.

The bear case assumes the recovery stalls. EPS grows only 1.6% a year to $23.16, and the multiple compresses to 13x as the market treats Medicare Advantage rate policy as a permanent headwind. The price target is $300, a 20% loss from today. Dividends, paid at current levels or slightly higher over ten years, offset enough of that loss to leave a total return near 0.5% before inflation. That passes the framework's absolute requirement of a non-negative bear case, but it fails the investment objective. The downside is a flat nominal outcome, not a permanent capital loss, unless a reputational or enforcement event is far worse than current facts suggest.

The bull case assumes Medicare Advantage rate adequacy improves after 2026, Optum captures share in the 40-plus biosimilar launches expected by 2027, and right-sizing returns margins to prior peak. EPS grows 10% a year to $51.24, and the multiple expands to 20x. The price target is $1,025 for a 12.8% total return. The bull case is plausible but not the base case because CMS policy and medical cost inflation remain outside management control.

The probability-weighted return is 7.5%, above the inflation-plus-4% hurdle and far above the 4% cash alternative. The spread over the hurdle is narrow, which supports a standard position size rather than a maximum position. The bear case demonstrates the preservation feature: a 20% terminal price loss is meaningful, but the dividend income keeps the total return from going materially negative over a ten-year holding period.

---

6. RISK ASSESSMENT

Regulatory risk is the dominant threat. The Business Breakdowns source documents Medicare Advantage scrutiny targeting coding intensity and billing practices. The Wall Street Journal raised fraud questions about risk coding in UnitedHealth's Medicare Advantage business, noting discrepancies between diagnosis coding and care documentation. The Department of Justice investigated Optum's algorithms. These are not settled items. A material enforcement action or coding settlement could reduce future revenue and force multi-year remediation costs. The stock already de-rated on these headlines, but the legal exposure remains visible.

Cyber and third-party risk follows. Change Healthcare, acquired in 2022, suffered a serious cyberattack in 2024 that interrupted medical payments. UnitedHealth depends on partners and contractors to handle protected data. The company monitors third-party controls and business continuity, but a proven breach shows the residual risk. A second systemic incident would damage the Optum services franchise and could cause immediate revenue loss.

Operational risk is also material. The company is deliberately shrinking unprofitable ACA individual membership by about one third in 2026, and total domestic membership fell from 49.8 million at the end of 2025 to 49.1 million in Q1 2026. Medicaid managed care membership is down about 3% on redeterminations, at 7.16 million trailing. If pricing does not offset volume loss fast enough, the 2026 operating earnings target above $24 billion becomes difficult to reach.

Financial risk is visible in the numbers. Net margin fell to 2.7% in 2025 from 6.0% in 2023. Adjusted EPS fell 41% from the 2024 peak of $27.66 to the 2025 figure near $16.30. TradingKey cites a 60% price drop and raises the

question of structural versus cyclical issues. Leverage is moderate at debt to equity of 0.66, but debt to EBITDA is 3.39, and FCF has declined for two consecutive years. If the recovery stalls, the company would need to choose among dividends, buybacks, and debt reduction.

Investor alignment and ESG risk are present but not terminal. ICCR filed a shareholder resolution asking the board to report on public health costs from practices that limit or delay access to care. Governance scores 70 to 80, which is strong, but the provider advises verifying compensation alignment. No auditor warnings, restatements, or material weaknesses appear in the filing data. That limits the probability of a total loss to below 5% in my qualitative assessment.

Macro sensitivity is moderate. Medical cost inflation above 7% is pushing employers toward self-insured and fee-based arrangements. That shift pressures premium revenue but can also raise Optum fee-based earnings. UnitedHealth's earning power remains tied to U.S. healthcare spending, which is durable in recession but subject to policy intervention.

---

7. MANAGEMENT & GOVERNANCE

The source packet does not provide CEO tenure or detailed compensation figures. Governance changes are visible. F. William McNabb became lead independent director, succeeding Michele Hooper, who remains on the board. The company added new independent directors with regulatory and clinical backgrounds. The board refreshed membership across the Audit and Finance, Compensation and Human Resources, Governance, and Health and Clinical Practice Committees. Those changes appear to respond directly to the coding and prior authorization scrutiny.

Insider activity conflicts by source. Yahoo Finance shows 47,591 shares purchased by insiders in the last six months across 54 transactions and 1,300 shares sold across 2 transactions, for net purchases of 46,291 shares and total insider holdings of 2.23 million shares. ChartMill reports zero insider buys in the last three and twelve months. An SEC Form 4 cluster from December 18, 2025 and a June 25, 2026 dividend-equivalent grant by director Valerie Montgomery Rice confirm some insider-level activity. I treat the Yahoo figure as indicative but not fully corroborated. Net insider buying, if accurate, aligns incentives, but insider ownership of 0.17% is low.

Capital allocation over the past five years includes the acquisitions of Change Healthcare in 2022 and LHC Group in 2023. FCF was $13.86 billion in one PitchGrade source and $16.08 billion in fiscal 2025 per StockAnalysis. The company raised $3 billion in senior notes across 2028 to 2055 maturities. The dividend has been maintained for 24 years. The packet does not detail buyback activity at specific prices, so I cannot judge whether repurchases were accretive or value destructive.

One red flag is vague. TradingKey mentions executive chaos as part of the 2024 decline but gives no names or dates. That is a headline-level statement, not a verified governance failure. The governance rating is strong, but the ESG provider recommends cross-checking management compensation. I score management quality as GOOD rather than EXCELLENT because the regulatory and cyber events occurred on the current board's watch and compensation alignment is not verified.

---

8. PEER COMPARISON

The research packet did not include numeric peer multiples for Elevance, Cigna, Humana, or CVS Health. I will not fabricate them. The comparative evidence available is qualitative and market-share based.

Dimension	UNH	Peer/Sector Signal
U.S. accident and health market share	33.8% (Q3 2025)	Sector leader by a wide margin
Medicare Advantage local dominance	Largest in 41% of counties; sole at least 50% in 22% (2024)	Scale and concentration
Overall industry rank	4/10 against 100 Health Care Providers peers (ChartMill)	Mid-to-low; financial health concerns
Profitability rank	In line with industry average (ChartMill)	Middle
Growth rank	Decent (ChartMill)	Middle
Dividend rank	Excellent (ChartMill)	Above sector
Financial health rank	Concerns (ChartMill)	Below peer median

The ChartMill 4/10 overall rank against 100 peers is the most direct sector comparison available. UnitedHealth rates above peers on dividends and in line on profitability and growth, but below median on financial health. That matches the financial fortress analysis: the scale and dividend are strong, while the balance sheet and recent margin compression are the weak points.

Against managed care peers, the key differentiator is not price but scale. A 33.8% market share plus Optum gives UnitedHealth provider pricing leverage that smaller insurers cannot match. The risk is that regulators target exactly that scale. You are paying a forward P/E near the sector's historical average for that scale, not a deep discount. If financial health were stronger, the quality score would push the composite above 75.

---

9. KEY METRICS SUMMARY

Metric	Value
Ticker	UNH
Current Price	$375.93 USD / €325.71 EUR
Market Capitalization	Approximately $342.5 billion (911 million shares)
FY2025 Revenue	$447.57 billion
FY2025 Net Income	$12.06 billion to $12.81 billion (source conflict)
FY2025 Diluted EPS	$13.23
Trailing Revenue	$450.53 billion
Trailing EPS	$15.26 to $15.54
Forward 2026 Consensus EPS	Approximately $19.76
P/E Trailing	24.4x
Forward P/E	19.11x

Metric	Value
P/S Trailing	0.78
P/B	3.3 to 3.4
P/FCF Trailing	17.8
EV/EBITDA	12.3
Debt / Equity	0.66
Debt / EBITDA Trailing	3.39
FY2025 FCF	$16.08 billion
Trailing FCF	Approximately $19.7 billion
Dividend	$2.21 quarterly / $8.84 annual (conflict: Yahoo lists $2.32)
Dividend Yield	2.35%
Trailing Payout Ratio	57% to 58%
Forward Payout Ratio	44.7%
ROIC Trailing	10.02%
ROE Trailing	14.15% to 16.53%
2025 Medical Care Ratio	89.1%
2026 Medical Care Ratio Guidance	88.8% +/- 50 basis points
Total Domestic Members Q1 2026	49.1 million

---

10. MONITORING CHECKLIST

Monitor	Frequency	Trigger	Action
Consolidated medical care ratio	Quarterly	Two consecutive quarters at or above 89.3%	Review exit; repricing failed
2027 Medicare Advantage rate decision	Event-driven	Final rate cut materially worse than guidance	Re-evaluate thesis
Membership mix	Quarterly	Risk-based commercial declines continue	Monitor or reduce
Optum margin	Quarterly	Compliance costs spike	Review services thesis
DOJ / algorithm enforcement	Event-driven	Material settlement or fraud admission	Sell or materially reduce
Dividend	Quarterly	Any cut	Sell immediately
Forward P/E	Ongoing	Above 24x without earnings acceleration	Thesis
Debt / EBITDA	Quarterly	Above 4.0x	Lower conviction
Biosimilar transitions	Event-driven	PBM margin compression	Reassess Optum

---

11. MARKET EXPECTATIONS & CONSENSUS

Consensus is constructive but not euphoric. MarketWatch reports 30 ratings: 19 Buy, 5 Overweight, 5 Hold, 1 Underweight, and 0 Sell. The average target is $481.52. MarketBeat reports 27 analysts, a Moderate Buy, a $456.56 average target, and 20.5% upside. Barchart reports 26 analysts with 16 Strong Buy, 2 Moderate Buy, 7 Hold, and 1 Strong Sell. The single Strong Sell is the main caveat; the distribution is not uniformly bullish.

The current stock price implies roughly 17% annual growth according to the search summary. Yahoo Finance explains that at roughly 15.5x earnings, maintaining the multiple while achieving the projected earnings recovery could generate about 17% annualized returns, or a 134% total return. That implied growth is higher than the conservative base case here because consensus expects a faster EPS recovery.

Metric	Value	vs Sector Avg	Assessment
Forward P/E	19.11	Not provided	Close to historical approximately 18x
PEG	1.46	Not provided	Moderate
EV/EBITDA	12.3	Not provided	Moderate
Beta	Not provided	Not provided	Cannot assess factor exposure directly
Analyst consensus	Overweight / Moderate Buy	Positive	Upside approximately 20% to 28%
Short interest	Not provided	Not provided	Verify separately

Recent revisions show a cluster of target increases after the July 16, 2026 Q2 beat. Morgan Stanley raised to $529, J.P. Morgan to $516, KeyBanc, Oppenheimer, and Truist to $500. Baird upgraded to Neutral with a $453 target from $287. The laggards are TD Cowen at $430 and HSBC at $380. The revision momentum is supportive. What would validate the consensus: EPS reaching approximately $26.8 by 2028 and revenue misses below 2%. What would disappoint: persistent MA rate cuts, a failure to close the 41% EPS decline, and multiple compression below 15.5x. Short interest is not in the packet, which is a data gap.

---

12. KEY BUSINESS DRIVERS

Driver 1: Consolidated medical care ratio (MCR)

Why it matters: This ratio measures whether premiums cover medical costs, the core insurance economics.

Current level: 2025 actual 89.1%; 2026 guidance 88.8% plus or minus 50 basis points; Q1 83.9%; Q2 86.7% versus 88.5% consensus.

Bull threshold: Full-year 2026 at or below 88.3%.

Bear threshold: Full-year 2026 at or above 89.3%.

Next data point: Q3 2026 earnings on October 27, 2026.

Driver 2: Net margin expansion on deliberate revenue decline

Why it matters: Management is right-sizing the premium mix, so margin must offset shrinking revenue.

Current level: 2025 net margin 2.7%; 2026 guidance approximately 3.6%; revenue projected above $439 billion, down 2%.

Bull threshold: Net margin at or above 3.6% with revenue above $439 billion.

Bear threshold: Net margin below 3.0% with revenue below $439 billion.

Next data point: Quarterly earnings releases.

Driver 3: Membership mix

Why it matters: Risk-based versus fee-based membership changes revenue quality and capital requirements.

Current level: Q2 total commercial domestic 29.92 million versus 29.53 million consensus; risk-based commercial 7.66 million versus 7.26 million; fee-based 22.27 million versus 22.27 million; total domestic members 49.1 million at Q1.

Bull threshold: Risk-based commercial stabilizes as pricing improves.

Bear threshold: ACA and Medicaid losses exceed plan and risk-based membership falls sharply.

Next data point: Quarterly earnings releases.

Driver 4: Medicare Advantage rate adequacy and the 2027 selling season

Why it matters: Medicare Advantage is the largest policy-driven margin source.

Current level: CMS rate adequacy expected to improve post-2026.

Bull threshold: 2027 rates cover medical cost inflation.

Bear threshold: 2027 cuts worsen and MA enrollment declines.

Next data point: CMS rate announcement date not provided; watch Q3 and Q4 commentary.

Driver 5: Optum biosimilar capture

Why it matters: More than 40 biosimilars are expected by 2027, creating margin opportunity and script pressure.

Current level: PBM formulary transition execution not quantified.

Bull threshold: Optum margin expands on biosimilar formulary share.

Bear threshold: Revenue per script pressure dominates.

Next data point: Quarterly Optum release.

---

13. PROXY TRACKERS & LEADING INDICATORS

Proxy	Ticker	Relationship	Signal
Health Care Select Sector SPDR	XLV	Sector risk appetite	Bullish if XLV holds the 50-day MA; bearis
Elevance Health	ELV	Managed care peer	Bullish if ELV holds on MA commentary; b
Humana	HUM	Medicare Advantage rate sensitivity	Bullish if HUM rallies after MA rate news;
CVS Health	CVS	PBM and healthcare services peer	Bullish if CVS stabilizes PBM margins; be

Monitoring rule: If XLV and ELV both close below their 50-day moving averages while UNH is above its own, treat the divergence as an early warning and re-examine the thesis within five trading days.

EXIT TRIGGERS

If the recommendation is BUY, the following items trigger a sell or re-review:

- MCR prints at or above 89.3% for two consecutive quarters: reduce or exit; the repricing thesis fails.
- The 2027 Medicare Advantage final rate cut is materially worse than guidance: re-evaluate the entire thesis.
- A DOJ or algorithm enforcement action, or a Medicare Advantage coding settlement, exceeds $10 billion or requires a fraud admission: sell.
- Any dividend cut: sell immediately.
- Forward P/E exceeds 24x without accelerating earnings recovery: trim.
- A second Optum cyber or data incident causes a multi-day payment disruption: review.
- 2026 revenue declines more than 2% with net margin below 3.0%: reduce.

FINAL RECOMMENDATION

RECOMMENDATION: BUY

At $375.93, UnitedHealth passes the absolute wealth preservation gates. The bear case total return is near 0.5%, the base case clears 7%, solvency is adequate, the dividend is sustainable, and the probability of a 50% permanent loss is below 5% in the qualitative assessment. The composite wealth preservation score is 66 out of 100, which places UNH in the standard position band.

Use a standard position size of EUR 75 on the framework scale, approximately 7.5% of a concentrated portfolio if that scale is used. Fair value in the base case is $500, a 33% margin of safety. Reassess after the October 27, 2026 earnings release.

ANALYST NOTES

Key Assumptions:

- Ten-year investment horizon.
- 2026 consensus EPS of $19.76 as the base starting point; long-term EPS growth of 6.5%; terminal P/E of 18x.
- Annual dividend of $8.84 based on the $2.21 quarterly figure; forward dividend growth of 5.0%.
- Fair value of $500 from the Stockoscope DCF and blended estimates.
- Exchange rate of €0.8664 per $1 from the provided current price.

Limitations:

- Missing interest coverage, current ratio, five-year valuation averages, dividend growth history, peer financials, short interest, and beta.
- Company guidance was not provided directly; 2026 operating targets come from the 2026 outlook document in the packet.
- Source conflicts exist for net income, market capitalization, dividend amount, insider activity, and analyst estimates.

Framework Gate Results:

- Stage 1 sector filter: CONTINUE.
- Stage 2 solvency: ADEQUATE.
- Earnings quality: ACCEPTABLE.
- Dilution: ACCEPTABLE but unverified five-year trend.
- Dividend: SUSTAINABLE.
- Capital efficiency: ROIC 10.02%, marginal value creation.
- Valuation: ATTRACTIVE with 33% margin of safety.
- Composite WP Score: 66/100.

Confidence Level: MEDIUM. The recovery thesis is supported by Q1 and Q2 2026 beats and the July 2026 sell-side upgrade cluster, but regulatory risk and missing data prevent HIGH confidence.

Report prepared for Moschovakis Capital. This analysis is for informational purposes only.

CONTINUE THE RESEARCH

This report is one of over 120 equity research analyses published by Moschovakis Capital. Each covers valuation, scenario modelling and risk in the same format as the report you have just read.

Full equity research archive

Latest published research

Enquiries and coverage requests

moschovakiscapital.com

IMPORTANT DISCLOSURES

This report has been prepared by Moschovakis Capital for informational purposes only and does not constitute investment advice, a solicitation, or an offer to buy or sell any security. The information contained herein is based on sources believed to be reliable but is not guaranteed as to accuracy or completeness. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Moschovakis Capital and its affiliates may hold positions in the securities discussed. This document is confidential and intended solely for the recipient. Any reproduction or distribution without prior written consent is prohibited.

EXECUTION INFRASTRUCTURE

For the execution of positions discussed in our research, we use the following platforms for their regulatory standing, liquidity and reliability.

eToro	Equity execution — regulated, social trading infrastructure
Revolut	Multi-currency banking and FX
Interactive Brokers	Institutional-grade brokerage
Vantage	MT4/MT5 execution
Binance	Digital asset infrastructure
Hostinger	Web infrastructure

Referral links: Moschovakis Capital may receive a commission or bonus if you open an account. It does not affect our research.